Get the Stockscreener App
32.88
4.05%
-1.3987
Mineralys Therapeutics Inc stock is traded at $32.88, with a volume of 338.97K.
It is down -4.05% in the last 24 hours and down -11.94% over the past month.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.
See More
Previous Close:
$34.28
Open:
$33.84
24h Volume:
338.97K
Relative Volume:
0.23
Market Cap:
$2.60B
Revenue:
-
Net Income/Loss:
$-119.67M
P/E Ratio:
-12.04
EPS:
-2.73
Net Cash Flow:
$-97.30M
1W Performance:
+0.46%
1M Performance:
-11.94%
6M Performance:
+147.11%
1Y Performance:
+220.57%
1-Day Range:
$32.73
$34.22
1-Week Range:
$30.96
$34.65
52-Week Range:
$8.241
$47.65
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
Name
Mineralys Therapeutics Inc
Sector
Industry
Phone
(888) 378-6240
Address
150 N. RADNOR CHESTER ROAD, RADNOR
Compare MLYS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
32.88 | 2.71B | 0 | -119.67M | -97.30M | -2.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.63 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.34 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
811.57 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.84 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-11-25 | Initiated | Jefferies | Hold |
| Jul-10-24 | Initiated | H.C. Wainwright | Buy |
| Apr-02-24 | Initiated | Goldman | Buy |
| Mar-07-23 | Initiated | BofA Securities | Buy |
| Mar-07-23 | Initiated | Credit Suisse | Outperform |
| Mar-07-23 | Initiated | Evercore ISI | Outperform |
| Mar-07-23 | Initiated | Guggenheim | Buy |
| Mar-07-23 | Initiated | Stifel | Buy |
| Mar-07-23 | Initiated | Wells Fargo | Overweight |
View All
Mineralys Therapeutics Inc Stock (MLYS) Latest News
Mineralys Therapeutics’ Earnings Call Highlights Positive Outlook - MSN
Relative Strength Alert For Mineralys Therapeutics - Nasdaq
Rodman sells Mineralys (MLYS) shares for $13,353 - Investing.com
Rodman sells Mineralys (MLYS) shares for $13,353 By Investing.com - Investing.com Nigeria
David Malcom Rodman Sells 416 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock - MarketBeat
Mineralys Awards New Hire Stock Option as Hypertension Pipeline Advances - MSN
Fed Watch: What is Mineralys Therapeutics Incs revenue forecast2025 Market Overview & Smart Swing Trading Alerts - baoquankhu1.vn
Activity Recap: Is EKSO a potential multi baggerAnalyst Upgrade & Fast Moving Stock Watchlists - baoquankhu1.vn
Are Mineralys Therapeutics’ (MLYS) Executive Stock Plans Aligned With Lorundrostat’s Emerging Investment Story? - Sahm
Insider Selling: Mineralys Therapeutics (NASDAQ:MLYS) Insider Sells 7,709 Shares of Stock - MarketBeat
David Malcom Rodman Sells 11,367 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock - MarketBeat
Sell Signal: Is Mineralys Therapeutics Inc. part of any major index2025 Earnings Impact & Free High Return Stock Watch Alerts - baoquankhu1.vn
Mineralys Therapeutics CEO Congleton sells $529k in MLYS stock By Investing.com - Investing.com India
Mineralys Therapeutics (NASDAQ:MLYS) CEO Sells $529,618.32 in Stock - MarketBeat
Levy, Mineralys Therapeutics CFO, sells $345k in MLYS stock By Investing.com - Investing.com Canada
Mineralys Therapeutics MLYS officer sells $277k in stock By Investing.com - Investing.com South Africa
Mineralys Therapeutics (NASDAQ:MLYS) Insider Sells $72,195.90 in Stock - MarketBeat
Mineralys Therapeutics (NASDAQ:MLYS) Insider Sells $205,167.36 in Stock - MarketBeat
Mineralys Therapeutics (NASDAQ:MLYS) CFO Sells $345,762.12 in Stock - MarketBeat
Levy, Mineralys Therapeutics CFO, sells $345k in MLYS stock - Investing.com
Mineralys Therapeutics MLYS officer sells $277k in stock - Investing.com
Buybacks Report: Will Mineralys Therapeutics Inc outperform tech stocksQuarterly Risk Review & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Patterns Watch: Whats Mineralys Therapeutics Incs historical returnJuly 2025 Rallies & Safe Capital Investment Plans - baoquankhu1.vn
Mineralys Targets Sleep Apnea and Hypertension With Lorundrostat: What Investors Should Watch - TipRanks
Mineralys Therapeutics, Inc. (MLYS) Stock Analysis: Unveiling a 54% Upside Potential in the Biotech Arena - DirectorsTalk Interviews
Insider Sell: CEO Jon Congleton Sells Shares of Mineralys Therap - GuruFocus
Discipline and Rules-Based Execution in MLYS Response - Stock Traders Daily
Trend Recap: Whats the RSI of Mineralys Therapeutics Inc stockJuly 2025 PostEarnings & Reliable Breakout Forecasts - baoquankhu1.vn
Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - ADVFN
Will Mineralys Therapeutics Inc. stock benefit from AI adoptionJuly 2025 Outlook & Risk Adjusted Buy/Sell Alerts - Улправда
Mineralys Therapeutics (MLYS) Stock Analysis Report | Financials & Insights - Benzinga España
Can Mineralys Therapeutics Inc. stock attract ESG capital inflowsEarnings Risk Summary & Weekly Breakout Watchlists - ulpravda.ru
Mineralys Therapeutics (NASDAQ:MLYS) Shares Down 7%Here's What Happened - MarketBeat
Is Mineralys Therapeutics Inc. stock a contrarian buyJuly 2025 Breakouts & Verified Momentum Watchlists - Улправда
Why Mineralys Therapeutics Inc. stock could outperform in 2025Quarterly Growth Report & Free Fast Entry Momentum Trade Alerts - Улправда
Mineralys Flags Key Data Readouts as Lorundrostat Nears FDA Decision - mychesco.com
Mineralys Therapeutics, Inc.Common Stock (NQ: MLYS - FinancialContent
Mineralys Therapeutics Insider Sold Shares Worth $9,261,028, According to a Recent SEC Filing - marketscreener.com
Mineralys Therapeutics Sees Unusually High Options Volume (NASDAQ:MLYS) - MarketBeat
MLYSMineralys Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
Insider Selling: Mineralys Therapeutics (NASDAQ:MLYS) Insider Sells 70,037 Shares of Stock - MarketBeat
Mineralys Therapeutics (NASDAQ:MLYS) Insider Sells $6,748,879.30 in Stock - MarketBeat
Mineralys Therapeutics CMO Sells Over $9 Million in Company Stock - TradingView — Track All Markets
Mineralys Therapeutics(MLYS.US) Officer Sells US$9.26 Million in Common Stock - 富途牛牛
Mineralys Therapeutics: Lorundrostat’s Broad Efficacy, Favorable Safety, and Upside Indications Support Buy Rating on MLYS - TipRanks
Mineralys Therapeutics filed NDA for lorundrostat to U.S. FDA in late 2025 - marketscreener.com
Mineralys updates lorundrostat program and upcoming data milestones - TipRanks
Mineralys Therapeutics, Inc. (MLYS) Investor Outlook: Analyzing a Potential 42.67% Upside in the Biotech Sector - DirectorsTalk Interviews
Mineralys Therapeutics, Inc. Provides Corporate Update and Announces NDA Filing - TradingView — Track All Markets
Mineralys Therapeutics Provides Corporate Update and - GlobeNewswire
Will Mineralys Therapeutics Inc. stock maintain dividend yield2026 world cup usa national team round of 32 midfield engines build up play match prediction statistical analysis - Улправда
Mineralys Therapeutics Inc Stock (MLYS) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.38%
1.95%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):